Vol. 19/No. 18

Gene expression-based biomarkers associated with disease recurrence in patients with cutaneous squamous cell carcinoma may help in identifying a population subset considered to have high-risk disease.

Thomas F. Gajewski, MD, PhD, has made inroads in the field of cancer immunotherapy, most notably discovering the connections between the microbiome and clinical outcomes—findings that will enable the creation of microbiota-modulating interventions to improve outcomes in patients undergoing cancer treatments.

The dismal prognosis for patients with metastatic renal cell carcinoma has fueled an earnest quest for more effective treatments, culminating in a better understanding of the disease and regulatory approval of several new drugs and therapeutic combinations.

Pressure to reduce costs associated with biologics is one of the forces driving the rapid expansion of biosimilars, which are biological drugs that are very similar to already approved reference biologics in terms of potency, safety, and efficacy.

The battle over 340B continues in Congress, with multiple legislative initiatives.

Less than 5 years after BTK inhibition was introduced in hematologic malignancies, the need for strategies to address primary and secondary mechanisms of resistance has emerged.

Investigators are hopeful that M7824, a bifunctional fusion protein that inhibits the PD-L1 and TGF-β pathways, will improve immune system responses across tumor types.

Patients with early-stage breast cancer facing a high risk of recurrence would benefit from the expanded use of adjuvant therapy, according to updated guidelines from the American Society of Clinical Oncology.

Like clinicians elsewhere, investigators from the University of Colorado, Denver, struggled not only to predict the likelihood that a particular patient would do well with surgery alone but also to convey their estimates in terms that patients would understand.

Maurie Markman, MD, discusses the clinical benefit of early-stage trials.